Page 664 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

622 ANTIMÉTABOLITES

plusieurs tumeurs solides. D'autres dérivés sont à l'étude, parmi lesquels la tezacitabine
(FMdC), exemple de choix raisonné du substituant en 2' sur le sucre permettant l'accès
à des inhibiteurs plus efficaces de la RNA dont certains sont en essais cliniques.
BIBLIOGRAPHIE

LAM MERS M., FOLLMANN H., The ribonucleotide reductases - A unique group of metal-
loenzymes essential for cell proliferation, Structure and Bonding, 1983, 54, 27-91.
ASHLEY G.W., STUBBE J., lnhibitors of ribonucleoside diphosphate reductase activity.
International Encyclopedia of Pharmacology and therapeutics, Section 128 ; Cory J.G.
et Cary A.H. Eds, Pergamon Press, New York, 1989, 55-87.
STUBBE J., Ribonucleotide reductases, Adv. Enzymol., 1990, 63, 349-419.
CHOU T.S. et al., Stereospecific synthesis of 2-deoxy-2,2-difluororibonolactone and its
use in the preparation of 2'-deoxy-2',2'-difluoro-B-D-ribofuranosyl pyrimidine
nucleosides : the key rôle of selective crystallisation, Synthesis, 1992, 565-570.
LORI F. et al., Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 repli-
cation, Science, 1994, 266, 801-805.
ROBINS M.J. et al., Ribonucleotide reductase targets for chemotherapy ; mechanistic
aspects and biologically active agents, Nucleosides & Nucleotides, 1995, 14, 485-493.
REICHARD P., The evolution of ribonucleotide reduction, Trends Biochem. Sci., 1997,
22, 81-85.
Gemcitabine, Drugs of the future, 1997, 22, 902-906. Drugs of the future, 1990, 15, 794.
GERFEN G.J. et al., Characterization of a substrate-derived radical detected during the
inactivation of ribonucleotide reductase from Escherichia coli by 2'-fluoromethylene-
2'-deoxycytidine 5'-diphosphate, J. Am. Chem. Soc., 1998, 120, 3823-3835.
Didox, Drugs of the future, 1998, 23, 87. Drugs of the future, 1990, 15, 22.
FMdC (tezacitabine), Drugs of the future, 1999, 24, 502-510. Drugs of the future, 2001,
26, 502-503.
ROSENBERGER G. et al., The ribonucleotide reductase-inhibitortrimidox induces c-myc
and apoptosis of human ovarian carcinoma cells, Lite Sciences, 2000, 67,3131-3142.
LI J. et al., Syntheses and antitumor activities of patent inhibitors of ribonucleotide
reductase : 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarbazone (3-
AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-
soluble prodrugs, Curr. Med. Chem., 2001, 8, 121-133.